Mai, X. M., Mendelsohn, A., Marshall, J., Lin, N. D., McDermott, C., Pawloski, P. A., … Lockhart, C. (2023). Utilization and patient characteristics for the originator and biosimilar trastuzumab products in the United States. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (Vol. 32, pp. 166–167).

Mai, Xiaodan Melody, Aaron Mendelsohn, James Marshall, Nancy D. Lin, Cara McDermott, Pamala A. Pawloski, Aziza Jamal-Allial, et al. “Utilization and patient characteristics for the originator and biosimilar trastuzumab products in the United States.” In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 32:166–67, 2023.

Mai XM, Mendelsohn A, Marshall J, Lin ND, McDermott C, Pawloski PA, et al. Utilization and patient characteristics for the originator and biosimilar trastuzumab products in the United States. In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023. p. 166–7.

Mai, Xiaodan Melody, et al. “Utilization and patient characteristics for the originator and biosimilar trastuzumab products in the United States.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 32, 2023, pp. 166–67.

Mai XM, Mendelsohn A, Marshall J, Lin ND, McDermott C, Pawloski PA, Jamal-Allial A, Daniels KM, Walraven C, Djibo DA, Lockhart C. Utilization and patient characteristics for the originator and biosimilar trastuzumab products in the United States. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023. p. 166–167.